Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): the AVERROES trial

被引：0
|
作者：
Hart, R. G. [1 ]
Eikelboom, J. [2 ]
Yusuf, S. [3 ]
Gao, P. [3 ]
Paolasso, E. [4 ]
De Caterina, R. [5 ]
Husted, S. [6 ]
Connolly, S. J. [2 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[2] McMaster Univ, Hamilton, ON, Canada
[3] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[4] Inst Cardiovasc Rosario, Rosario, Santa Fe, Argentina
[5] Univ Cardiol Div Chieti, Chieti, Italy
[6] Aarhus Univ, Aarhus, Denmark
来源：
EUROPEAN HEART JOURNAL | 2011年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [21] PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION (AF) AND CHRONIC KIDNEY DISEASE (CKD): ARE DIRECT ORAL ANTICOAGULANTS (DOACS) SAFE AND EFFECTIVE COMPARED TO WARFARIN?
    Wiggam, T.
    Williamson, P.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (3_SUPPL) : 38 - 38
  • [22] Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease
    Petrov, Vladimir, I
    Shatalova, Olga, V
    Gerasimenko, Anastasia S.
    Gorbatenko, Vladislav S.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2019, 15 (04) : 530 - 537
  • [23] Oral anticoagulants in patients with chronic kidney disease and atrial fibrillation
    Prkacin, Ingrid
    Cavric, Gordana
    Adam, Visnja Nesek
    Balenovic, Diana
    Horvat, Ivan
    Dobrota, Vesna Dermanovic
    Radocaj, Tomislav
    [J]. SIGNA VITAE, 2016, 11 : 41 - 43
  • [24] Oral anticoagulation in patients with atrial fibrillation and chronic kidney disease
    Angel Sanchez-Munoz, Luis
    Arnaldo Aguilar-Flores, Rene
    Juanatey-Garcia, Ana
    Gonzalez de Zarate-Caton, Sara
    [J]. MEDICINA CLINICA, 2015, 144 (10): : 480 - 480
  • [25] Efficacy and safety of patients with chronic kidney disease undergoing left atrial appendage closure for atrial fibrillation
    Liu, Chaofan
    Han, Shaojie
    Cui, Kaijun
    Wang, Fang
    [J]. PLOS ONE, 2023, 18 (10):
  • [26] Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
    Rhee, Tae-Min
    Lee, So-Ryoung
    Choi, Eue-Keun
    Oh, Seil
    Lip, Gregory Y. H.
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [27] Apixaban: An orally active factor Xa inhibitor to prevent strokes and systemic embolism in patients with nonvalvular atrial fibrillation
    Sobieraj, Diana M.
    Coleman, Craig I.
    [J]. FORMULARY, 2012, 47 (05) : 180 - 183
  • [28] Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)
    Bansilal, Sameer
    Bloomgarden, Zachary
    Halperin, Jonathan L.
    Hellkamp, Anne S.
    Lokhnygina, Yuliya
    Patel, Manesh R.
    Becker, Richard C.
    Breithardt, Guenter
    Hacke, Werner
    Hankey, Graeme J.
    Nessel, Christopher C.
    Singer, Daniel E.
    Berkowitz, Scott D.
    Piccini, Jonathan P.
    Mahaffey, Kenneth W.
    Fox, Keith A. A.
    [J]. AMERICAN HEART JOURNAL, 2015, 170 (04) : 675 - +
  • [29] DIRECT FACTOR Xa INHIBITOR APIXABAN PREVENTS ENDOTHELIAL ACTIVATION AND DAMAGE ASSOCIATED WITH CHRONIC KIDNEY DISEASE
    Cases, Aleix
    Vera, Manel
    Palomo, Marta
    Torramade, Sergi
    Escolar, Gines
    Diaz-Ricart, Maribel
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [30] Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation (ROCKET AF)
    Patel, Manesh R.
    [J]. CIRCULATION, 2010, 122 (21) : 2217 - 2217
12345